OUTCOME OF PATIENTS WITH RELAPSED AND REFRACTORY PERIPHERAL T CELL LYMPHOMA INTENDED FOR STEM CELL TRANSPLANT
Sign Up to like & getrecommendations! Published in 2017 at "Hematological Oncology"
DOI: 10.1002/hon.2438_104
Abstract: OUTCOME OF PATIENTS WITH RELAPSED AND REFRACTORY PERIPHERAL T CELL LYMPHOMA INTENDED FOR STEM CELL TRANSPLANT S. Parkin* | S. Wong | J.M. Connors | L. Sehn | D. Villa | A. Gerrie | R.… read more here.
Keywords: relapsed refractory; refractory peripheral; outcome patients; patients relapsed ... See more keywords
A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas
Sign Up to like & getrecommendations! Published in 2024 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-24-1913
Abstract: Abstract Purpose: Patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL) generally have poor prognoses and limited treatment options. This study evaluated the efficacy of a novel CD30/CD16A bispecific innate cell engager, acimtamig (AFM13),… read more here.
Keywords: refractory peripheral; response; cell; acimtamig afm13 ... See more keywords
Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2021.789891
Abstract: Patients with relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL) have a poor prognosis, with an expected survival of less than 1 year using standard salvage therapies. Recent advances in our understanding of the biology of PTCL… read more here.
Keywords: refractory peripheral; cell lymphoma; venetoclax; relapsed refractory ... See more keywords